Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the biotech and pharmaceutical industries, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Bio-Techne Corporation and Bausch Health Companies Inc. have demonstrated contrasting approaches to SG&A optimization.

From 2014 to 2023, Bausch Health's SG&A expenses fluctuated, peaking in 2023 with a 44% increase from 2014. In contrast, Bio-Techne's expenses grew steadily, with a notable 522% rise over the same period. This suggests a strategic expansion and investment in administrative capabilities.

While Bausch Health's expenses remained relatively stable, Bio-Techne's consistent growth indicates a focus on scaling operations. However, the absence of data for Bausch Health in 2024 leaves room for speculation on future trends. As these companies navigate the complexities of their industries, their SG&A strategies will continue to play a pivotal role in their financial health.